Does the GCKR rs1260326 variant raise circulating SHBG levels?

The relationship between the GCKR rs1260326 genetic variant and circulating sex hormone-binding globulin (SHBG) levels is well-documented in genetic research, but the evidence indicates a direction of effect opposite to the original claim.

Clinical and Genetic Evidence

Genetic studies consistently show that the rs1260326 variant is associated with decreased, rather than increased, SHBG concentrations.

• Directional Effect: Research involving both fertile and infertile male populations has demonstrated that the C-allele (the variant allele encoding Pro446Leu) is associated with an allelic effect of -2.2 per C-allele (p = 1.5 × 10⁻⁴), indicating a significant reduction in serum SHBG levels.
• Large-Scale Findings: While large-scale Genome-Wide Association Study (GWAS) meta-analyses identify the GCKR locus as a primary regulator of SHBG concentrations, the minor allele at this specific locus consistently correlates with lower circulating levels across various cohorts.

Mechanistic Explanations

The GCKR gene encodes the glucokinase regulatory protein (GKRP), which modulates the activity of glucokinase (GCK) in the liver.

• Protein Alteration: The rs1260326 (P446L) mutation weakens the inhibitory binding between GKRP and GCK.
• Metabolic Shift: This leads to increased GCK translocation and activity within hepatocytes, which enhances hepatic glucose uptake and stimulates de novo lipogenesis.
• SHBG Synthesis: Although the exact signaling pathway connecting increased GCK activity to reduced SHBG production is still being clarified, the metabolic environment created by this variant—characterized by higher hepatic fat and lower fasting glucose—is robustly linked to decreased SHBG synthesis in the liver.

Bottom line

The GCKR rs1260326 (Pro446Leu) variant is statistically associated with lower circulating SHBG levels, not higher. The claim is unsupported as it misidentifies the direction of the genetic association.